Dr. Jonathan Trent on FDA Approval of Trabectedin for Soft Tissue Sarcomas
13 Views
administrator
07/18/23
Jonathan C. Trent, MD, professor of Medicine, co-director, Musculoskeletal Center, Sarcoma Medical Research Program, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the FDA approval of trabectedin for patients with soft tissue sarcomas.
-
Category
Show more
Facebook Comments
No comments found